This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
admitted for acute heart failure to the Kitasato University Hospital.
From the life-year analysis with 3% discount rate in costs, the total medical expenses were estimated to be Y2,764,769 in the conventional group and Y1,445,439 in the carvedilol group. From the 5-year analysis with a 3% discount rate for costs, the total medical expenses were estimated to be Y2,916,626 in the conventional group and Y1,526,986 in the carvedilol group.
Carvedilol treatment incurred higher outpatient costs and drug costs than conventional therapy. However, the cost of conventional therapy for acute care for CHF offset the previous costs incurred by the carvedilol treatment because patients in this group experienced fewer events.
Synthesis of costs and benefits
The costs and effects were not combined in an incremental analysis as carvedilol always dominated the conventional therapy. The sensitivity analysis showed that the baseline results were robust.
Authors' conclusions
Carvedilol treatment for chronic heart failure (CHF) is a highly cost-effective method of therapy in the Japanese setting.
CRD COMMENTARY -Selection of comparators
The authors provided sufficient and clear evidence for the comparator chosen. Treatment with beta-blockers seemed to be an effective alternative for mild and moderate patients with CHF in the USA and Europe. The authors aimed to provide evidence for the Japanese setting. Concomitant use of ACE inhibitors, diuretics and digitalis appear to represent current practice in the authors' setting. You should decide if this is widely used health technology in your own setting.
Validity of estimate of measure of effectiveness
The authors used a large, double-blind, placebo-controlled trial to obtain the effectiveness data and augmented this with estimates derived from other literature. The trial was not described in detail, but further information can be obtained from the published study. It is unclear whether this was the best source of evidence to obtain the parameters for the model, as the authors did not mention whether a relevant systematic review of the literature was available. This would have been a better source of evidence for the treatment effect parameters. The authors justified their selection of studies (e.g. monthly mortality rate) in terms of data relevant to the Japanese population.
Validity of estimate of measure of benefit
The estimation of benefits was obtained directly from the model. The authors stated that quality-adjusted life-years were not used as the utility values for Japanese patients at each stage of CHF were not available. The authors appear to have used the outcomes defined in the effectiveness paper as the measure of benefit, probably because they are the end points defined in other trials, thus allowing them to compare the results obtained.
Validity of estimate of costs
All the relevant categories of costs were included for the perspective adopted. However, the source of evidence for outpatient management was not stated and this may limit the generalisability of the results obtained. The fact that there was no detailed information on what exactly was included in each category makes the costing exercise somewhat difficult to understand and compare with other similar studies. The omission of critical treatment medical costs for cases of mortality because of worsening of heart failure seems unlikely to have affected the results, as the authors provided sufficient justification for the omission. Resource use was unclear and only one figure (for hospitalisation) was presented. This may well influence the generalisability of the results to other settings and also the comparison of this cost-effectiveness study with similar published evidence. The source of the unit costs was not clear, but was likely to have been the reimbursement rate set by the Japanese health care insurance system (as this was the chosen perspective).
